The GLP-1 Pill Wars: Novo Nordisk’s Comeback and the $100B Obesity Market
The pharmaceutical landscape is currently dominated by a single, revolutionary class of drugs: GLP-1 receptor agonists. What began as a…
Category: Biotech
Novo Nordisk (NVO): Navigating the New Era of the GLP-1 Revolution
Novo Nordisk (NYSE: NVO), the Danish pharmaceutical titan that catalyzed the global GLP-1 weight-loss revolution, finds itself at a critical…